Profile data is unavailable for this security.
About the company
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segment’s services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
- Revenue in USD (TTM)1.10bn
- Net income in USD2.13m
- Incorporated2016
- Employees1.93k
- LocationPetIQ IncPetiq Llc, 230 E. Riverside Dr.EAGLE 83616United StatesUSA
- Phone+1 (208) 939-8900
- Fax+1 (302) 655-5049
- Websitehttps://petiq.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Skye Bioscience Inc | 0.00 | -37.64m | 456.02m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Mersana Therapeutics Inc | 36.86m | -171.67m | 456.10m | 123.00 | -- | 12.30 | -- | 12.38 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Tourmaline Bio Inc | 0.00 | -42.12m | 458.05m | 44.00 | -- | 1.77 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Avid Bioservices Inc | 140.94m | -11.45m | 458.48m | 365.00 | -- | 2.50 | -- | 3.25 | -0.1816 | -0.1816 | 2.23 | 2.90 | 0.3144 | 3.18 | 5.49 | 386,131.50 | -2.55 | 10.73 | -3.11 | 14.01 | 12.52 | 22.72 | -8.12 | 25.92 | 0.8529 | -3.32 | 0.4502 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
Fulcrum Therapeutics Inc | 2.81m | -97.34m | 458.94m | 76.00 | -- | 1.95 | -- | 163.61 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Annexon Inc | 0.00 | -134.24m | 460.48m | 71.00 | -- | 1.60 | -- | -- | -1.78 | -1.78 | 0.00 | 3.20 | 0.00 | -- | -- | 0.00 | -46.07 | -44.06 | -49.49 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Larimar Therapeutics Inc | 0.00 | -36.95m | 461.91m | 42.00 | -- | 3.89 | -- | -- | -0.8416 | -0.8416 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -33.24 | -42.22 | -36.56 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Travere Therapeutics Inc | 145.24m | -376.33m | 468.07m | 380.00 | -- | 2.31 | -- | 3.22 | -4.98 | -1.50 | 1.96 | 2.66 | 0.1988 | 1.40 | 7.68 | 382,205.30 | -51.50 | -36.95 | -65.94 | -44.77 | 92.12 | 95.92 | -259.11 | -165.79 | 3.41 | -- | 0.6526 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
C4 Therapeutics Inc | 20.76m | -132.49m | 468.54m | 145.00 | -- | 1.68 | -- | 22.57 | -2.67 | -2.67 | 0.4181 | 4.07 | 0.0514 | -- | 3.13 | 143,144.80 | -32.82 | -25.91 | -36.80 | -29.45 | -- | -- | -638.34 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Theravance Biopharma Inc | 57.42m | -55.19m | 470.55m | 99.00 | -- | 2.19 | -- | 8.19 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Third Harmonic Bio Inc | 0.00 | -30.82m | 471.88m | 30.00 | -- | 1.73 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
PetIQ Inc | 1.10bn | 2.13m | 476.79m | 1.93k | 263.97 | 2.16 | 9.71 | 0.4327 | 0.0614 | 0.0614 | 35.69 | 7.52 | 1.31 | 5.63 | 8.46 | 570,079.10 | 0.301 | -4.32 | 0.3777 | -5.23 | 22.94 | 20.05 | 0.2304 | -3.66 | 1.43 | 1.74 | 0.6671 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
Editas Medicine Inc | 78.12m | -153.22m | 478.61m | 265.00 | -- | 1.37 | -- | 6.13 | -2.06 | -2.06 | 1.03 | 4.27 | 0.1542 | -- | 10.19 | 294,803.80 | -30.24 | -29.85 | -34.43 | -33.19 | -- | -- | -196.13 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Taysha Gene Therapies Inc | 15.45m | -111.57m | 481.57m | 52.00 | -- | 6.42 | -- | 31.17 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.16m | 7.41% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.07m | 7.08% |
Eos Management LPas of 31 Dec 2023 | 1.97m | 6.76% |
Aristotle Capital Boston LLCas of 31 Dec 2023 | 1.29m | 4.41% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.09m | 3.72% |
Boston Partners Global Investors, Inc.as of 31 Dec 2023 | 999.88k | 3.43% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 911.64k | 3.12% |
Nepsis, Inc.as of 31 Mar 2024 | 898.17k | 3.08% |
Driehaus Capital Management LLCas of 31 Dec 2023 | 732.16k | 2.51% |
Applied Fundamental Research LLCas of 31 Dec 2023 | 654.23k | 2.24% |